دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial
MiltonPackerMDabStefan D.AnkerMD, PhDcJavedButlerMD, MPHdGerasimosFilippatosMDeJoao PedroFerreiraMDfStuart J.PocockPhDgNaveedSattarMD, PhDhMartinaBrueckmannMDijWaheedJamalMDiDanielCottonMSkTomokoIwataMSlFaiezZannadMD, PhDfEMPEROR-Reduced Trial Committees and Investigators
doi : 10.1016/j.jacc.2021.01.033
Volume 77, Issue 11, 23 March 2021, Pages 1381-1392
Investigators have hypothesized that sodium-glucose cotransporter 2 (SGLT2) inhibitors exert diuretic effects that contribute to their ability to reduce serious heart failure events, and this action is particularly important in patients with fluid retention.
SGLT-2 Inhibitors in Heart Failure: Volume or Value??
Mikhail N.KosiborodMDabMuthiahVaduganathanMD, MPHc
doi : 10.1016/j.jacc.2021.02.005
Volume 77, Issue 11, 23 March 2021, Pages 1393-1396
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced
Jo?o PedroFerreiraMDaFaiezZannadMDaStuart J.PocockPhDbStefan D.AnkerMDcJavedButlerMDdGerasimosFilippatosMDeMartinaBrueckmannMDfgWaheedJamalMDfDominikSteublMDfElkeSchuelerDiplMathhMiltonPackerMDij
doi : 10.1016/j.jacc.2021.01.044
Volume 77, Issue 11, 23 March 2021, Pages 1397-1407
Mineralocorticoid receptor antagonists (MRAs) and sodium glucose co-transporter 2 inhibitors favorably influence the clinical course of patients with heart failure and reduced ejection fraction.
Quadruple Medical Therapy for Heart Failure: Medications Working Together to Provide the Best Care?
Stephen J.GreeneMDabMuhammad ShahzebKhanMD, MScc
doi : 10.1016/j.jacc.2021.02.006
Volume 77, Issue 11, 23 March 2021, Pages 1408-1411
Long-Term Outcomes of Patients Undergoing the Ross Procedure
AnasAboudMDab?Efstratios I.CharitosMD, PhDc?BuntaroFujitaMDabUlrichStierleMDaJan-ChristianReilMDdVladimirVothMDeMarkusLiebrichMDeMartinAndreasMDfTomasHolubecMDgConstanzeBeningMDhMarcAlbertMDiPetrFilaMDjJiriOndrasekMDjPeterMurinMDkRüdigerLangeMDlHermannReichenspurnerMDmUlrichFrankeMDiArminGorskiMDhAntonMoritzMDgGüntherLauferMDfWolfgangHemmerMDeHans-HinrichSieversMDaStephanEnsmingerMD, DPhilab
doi : 10.1016/j.jacc.2021.01.034
Volume 77, Issue 11, 23 March 2021, Pages 1412-1422
Treatment of aortic-valve disease in young patients still poses challenges. The Ross procedure offers several potential advantages that may translate to improved long-term outcomes.
The Ross Procedure in Adults: The Ideal Aortic Valve Substitute??
IsmailEl-HamamsyMD, PhDaCarole A.WarnesMDbRick A.NishimuraMDb
doi : 10.1016/j.jacc.2021.01.041
Volume 77, Issue 11, 23 March 2021, Pages 1423-1425
Atherosclerotic Carotid Plaque Composition and Incident Stroke and Coronary Events
DanielBosMD, PhDabBanafshehArshiMD, MScaQuirijn J.A.van den BouwhuijsenMDabM. KamranIkramMD, PhDacMarianaSelwanessMD, PhDbMeike W.VernooijMD, PhDabMaryamKavousiMD, PhDa?Aadvan der LugtMD, PhDb?
doi : 10.1016/j.jacc.2021.01.038
Volume 77, Issue 11, 23 March 2021, Pages 1426-1435
Increasing evidence suggests that atherosclerotic plaque composition rather than plaque size is linked to ischemic cardiovascular events, yet largescale population-based data in asymptomatic individuals remain scarce.
From Risk Factors to Clinical Disease: New Opportunities and Challenges for Cardiovascular Risk Prediction?
Pier SergioSabaMD, PhDGuidoParodiMD, PhDAntonelloGanauMD
doi : 10.1016/j.jacc.2021.01.040
Volume 77, Issue 11, 23 March 2021, Pages 1436-1438
Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients
Camilla Ditlev LindhardtJohannesenMDabcMartin B?dtkerMortensenMD, PhDabcdAnneLangstedMD, PhDabcB?rge Gr?nneNordestgaardMD, DMScabc
doi : 10.1016/j.jacc.2021.01.027
Volume 77, Issue 11, 23 March 2021, Pages 1439-1450
In cholesterol guidelines, low-density lipoprotein (LDL) cholesterol remains the primary target while apolipoprotein B (apoB) and non–high-density lipoprotein (non-HDL) cholesterol are secondary targets.
Tracking Residual Risk: Time for a Change??
Neil J.StoneMDDonaldLloyd-JonesMD
doi : 10.1016/j.jacc.2021.01.035
Volume 77, Issue 11, 23 March 2021, Pages 1451-1453
Cardiac Rehabilitation for Patients With Heart Failure: JACC Expert Panel
BiykemBozkurtMD, PhDaGregg C.FonarowMDbLee R.GoldbergMD, MPHcMayaGuglinMDdRichard A.JosephsonMS, MDeDaniel E.FormanMDfGraceLinMDgJoAnnLindenfeldMDhChrisO’ConnorMDijGurusherPanjrathMDkIleana L.Pi?aMD, MPHlmTinaShahMDnShashank S.SinhaMD, MScijEugeneWolfelMDoACC’s Heart Failure and Transplant Section and Leadership Council
doi : 10.1016/j.jacc.2021.01.030
Volume 77, Issue 11, 23 March 2021, Pages 1454-1469
Cardiac rehabilitation is defined as a multidisciplinary program that includes exercise training, cardiac risk factor modification, psychosocial assessment, and outcomes assessment. Exercise training and other components of cardiac rehabilitation (CR) are safe and beneficial and result in significant improvements in quality of life, functional capacity, exercise performance, and heart failure (HF)–related hospitalizations in patients with HF. Despite outcome benefits, cost-effectiveness, and strong practice guideline recommendations, CR remains underused. Clinicians, health care leaders, and payers should prioritize incorporating CR as part of the standard of care for patients with HF.
A Personalized Approach to Chronic Kidney Disease and Cardiovascular Disease: JACC Review Topic of the Week
Ashton C.LaiMD, PhDa?Solomon W.BienstockMDa?RamanSharmaMDaKarlSkoreckiMDbFransBeerkensMDaRajeevSamtaniMDaAndrewCoyleMDaToniaKimMDaUsmanBaberMD, MSaAntonCamajMD, MSaDavidPowerMDaValentinFusterMD, PhDacMartin E.GoldmanMDa
doi : 10.1016/j.jacc.2021.01.028
Volume 77, Issue 11, 23 March 2021, Pages 1470-1479
Cardiovascular disease is the most common cause of death in patients with end-stage renal disease (ESRD). The initiation of dialysis for treatment of ESRD exacerbates chronic electrolyte and hemodynamic perturbations. Rapid large shifts in effective intravascular volume and electrolyte concentrations ultimately lead to subendocardial ischemia, increased left ventricular wall mass, and diastolic dysfunction, and can precipitate serious arrhythmias through a complex pathophysiological process. These factors, unique to advanced kidney disease and its treatment, increase the overall incidence of acute coronary syndrome and sudden cardiac death. To date, risk prediction models largely fail to incorporate the observed cardiovascular mortality in the CKD population; however, multimodality imaging may provide an additional prognostication and risk stratification. This comprehensive review discusses the cardiovascular risks associated with hemodialysis, and explores the pathophysiology and the novel utilization of multimodality imaging in CKD to promote a personalized approach for these patients with implications for future research.
Rural-Urban Disparities: Diabetes, Hypertension, Heart Disease, and Stroke Mortality Among Black and White Adults, 1999-2018
RahulAggarwalMDNicholasChiuMD, MPHEméfah C.LoccohBSDhruv S.KaziMD, MSRobert W.YehMD, MSRishi K.WadheraMD, MPP, MPhil
doi : 10.1016/j.jacc.2021.01.032
Volume 77, Issue 11, 23 March 2021, Pages 1480-1481
TRVD Therapy in Acute HF: Proof of Concept in Animal Model and Initial Clinical Experience
MarcVanderheydenMDJozefBartunekMD, PhDAleksandar N.NeskovicMD, PhDDavorMilicicMD, PhDJoelleKefferMD, PhDSrdjanKafedzicMD, PhDHrvojeJurinMD, PhDNicolasBorensteinDVMWilfriedMullensMD, PhDEhudSchwammenthalMD, PhD
doi : 10.1016/j.jacc.2021.01.029
Volume 77, Issue 11, 23 March 2021, Pages 1481-1483
Prasugrel Versus Ticagrelor in Non–ST-Segment Elevation Acute Coronary Syndrome
Chia SiangKowMPharmAbdullah FaizZaihanBPharmSyed ShahzadHasanPhD
doi : 10.1016/j.jacc.2020.12.061
Volume 77, Issue 11, 23 March 2021, Pages 1483-1484
Reply: Prasugrel Versus Ticagrelor in Non–ST-Segment-Elevation Acute Coronary Syndrome
Franz-JosefNeumannMDChristianValinaMDAdnanKastratiMD
doi : 10.1016/j.jacc.2021.01.009
Volume 77, Issue 11, 23 March 2021, Page 1484
Acute Idiopathic Pericarditis: Is it Actually Always Idiopathic?
GeorgeLazarosMD, PhDCharalambosVlachopoulosMD, PhDEmiliaLazarouMDDimitrisVassilopoulosMD, PhDCostantinosTsioufisMD, PhD
doi : 10.1016/j.jacc.2020.12.064
Volume 77, Issue 11, 23 March 2021, Pages 1484-1485
Reply: Acute Idiopathic Pericarditis: Is it Actually Always Idiopathic?
Flora LindSigvardtMDMorten LockHansenMD, PhDChristianMadelaireMD
doi : 10.1016/j.jacc.2021.01.025
Volume 77, Issue 11, 23 March 2021, Pages 1485-1486
